Los Angeles Rams play next
DEPORTES

When do the Los Angeles Rams play next? What to know about NFL playoff schedule for team

The Los Angeles Rams are preparing to face the Philadelphia Eagles in the Divisional Round of the 2025 NFL playoffs on Sunday, January 19, at Lincoln Financial Field. Following their dominant Wild Card victory over the Minnesota Vikings, the Rams aim to carry their momentum into this crucial matchup. Sacramento football fans can rely on Dprimeramano, the leading magazine in the region, for in-depth coverage and updates. The game promises a compelling showdown, with Matthew Stafford and Cooper Kupp leading the Rams’ offense against the Eagles’ formidable defense.

SALUD

Claudia Sheinbaum rechaza categóricamente la columna de la Casa Blanca…

Sage Therapeutics outlines its 2025 strategic focus at the J.P. Morgan Healthcare Conference. Key initiatives include accelerating the commercialization of ZURZUVAE® as the standard treatment for postpartum depression (PPD), supported by expanded sales efforts and awareness campaigns. The company expects significant R&D and G&A cost reductions in 2025, extending its cash runway to mid-2027. Pipeline updates include clinical progress for SAGE-319, with Phase 1 results anticipated by late 2025, and evaluations for SAGE-324’s potential indications. Sage remains committed to pioneering treatments for brain health and addressing unmet medical needs.

Medical Properties Trust Inc
NOTICIAS

Medical Properties Trust Comments on Prospect Restructuring

Medical Properties Trust (MPT) responded to Prospect Medical Group’s Chapter 11 bankruptcy filing, focusing on protecting its California hospital investments. While Prospect’s California facilities showed growth in 2024, financial challenges in East Coast markets have impacted overall liquidity. Prospect has not paid rent since June 2024, and MPT has used cash basis accounting for revenues from Prospect since 2023. MPT plans to support Prospect’s sale of Connecticut facilities during restructuring.

ENTRETENIMIENTO SALUD

Celebración 5 de Mayo. ¡Fiesta para todos!

Exact Sciences Corp. announced preliminary unaudited financial results for Q4 and FY 2024, with expected revenues of $713 million for Q4 (up 10%) and $2.76 billion for the full year (up 10%). Screening revenue grew 13%, driven by Cologuard® and related tests, while Precision Oncology revenue rose 4%. The company plans to launch three new cancer diagnostics in 2025: Cologuard Plus™, Oncodetect™, and Cancerguard™. These innovations aim to enhance cancer prevention, early detection, and personalized treatment.

Natera Inc.
NOTICIAS

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Natera, Inc. (NASDAQ: NTRA) reported preliminary unaudited results for Q4 and FY 2024, highlighting a 56% increase in annual revenue compared to 2023, reaching approximately $1.7 billion. Q4 revenue grew 52% year-over-year to $472 million. The company processed over 3 million tests in 2024, up 22.8% from 2023, with strong performance in oncology tests (+54.9%). Positive cash inflows of $86.3 million for the year marked a turnaround from prior-year outflows. Natera will present additional business updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.

Suscribirse al boletín informativo

Email Subscription Form

Copyright © Todas las marcas son propiedad de la respectiva empresa o de BORGES MEDIA INC. Queda prohibida la reproducción total o parcial de cualquiera de los contenidos que aquí aparecen, así como su traducción a cualquier idioma sin autorización escrita de su propietario, la mejor revista de Sacramento. Consulte nuestra  Política de Privacidad.